Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease andaging

Neurobiology of Aging

Volumn 36, Issue 3, 2015, Pages 1529-1542

  Bar Am, Orit ^a   Amit, Tamar ^a   Kupershmidt, Lana ^a   Aluf, Yuval ^a   Mechlovich, Danit ^a   Kabha, Hoda ^a   Danovitch, Lena ^a   Zurawski, Vincent R ^a   Youdim, Moussa B H ^a,b   Weinreb, Orly ^a,b  

^a New Southern Industrial Park   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Aging; Iron chelation; Monoamine oxidase inhibition; Neurorestoration; Neurotrophic factors; Parkinson's disease

Indexed keywords

5 [2 (METHYL PROP 2 YNYL AMINO)ETHYL]QUINOLIN 8 OL DIHYDROCHLORIDE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIPARKINSON AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE GROWTH FACTOR; NEUROMODULIN; NEUROPROTECTIVE AGENT; PROTEIN BCL 2; SYNAPSIN I; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; 5-(2-(METHYLPROP-2-YNYLAMINO)ETHYL)QUINOLIN-8-OL; AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE; IRON CHELATING AGENT; MONOAMINE OXIDASE INHIBITOR; QUINOLINOL DERIVATIVE;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG POTENCY; ENZYME INHIBITION; GENE EXPRESSION; HIPPOCAMPUS; IC50; LIPID PEROXIDATION; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NEUROPROTECTION; NEURORESTORATIVE ACTIVITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; C57BL MOUSE; COGNITION; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PSYCHOLOGY; SPRAGUE DAWLEY RAT;

AGING; ANIMALS; COGNITION; DISEASE MODELS, ANIMAL; DOPAMINE; HYDROXYQUINOLINES; IRON CHELATING AGENTS; MALE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NERVE GROWTH FACTORS; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RATS, SPRAGUE-DAWLEY;

EID: 84923593287     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.10.026     Document Type: Article

References (55)

1. Akao Y., Maruyama W., Shimizu S., Yi H., Nakagawa Y., Shamoto-Nagai M., Youdim M.B., Tsujimoto Y., Naoi M. Mitochondrial permeability transition mediates apoptosis induced by N- methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J.Neurochem. 2002, 82:913-923.
2. Bar-Am O., Weinreb O., Amit T., Youdim M.B. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 2005, 19:1899-1901.
3. Barber A.J., Yu P.H., Boulton A.A. Chronic effects of monoamine oxidase-B inhibitors on the behaviour of aged mice. Life Sci. 1993, 53:739-747.
4. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J.Neurochem. 1991, 56:1441-1444.
5. Ben-Shachar D., Kahana N., Kampel V., Warshawsky A., Youdim M.B.H. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 2004, 46:254-263.
6. Blandini F., Armentero M.T., Fancellu R., Blaugrund E., Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp. Neurol. 2004, 187:455-459.
7. Borsini F., Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity?. Psychopharmacology (Berl) 1988, 94:147-160.
8. de Lima M.N., Laranja D.C., Bromberg E., Roesler R., Schroder N. Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behav. Brain Res. 2005, 156:139-143.
9. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. neurol 2002, 175:303-317.
10. Elgersma Y., Silva A.J. Molecular mechanisms of synaptic plasticity and memory. Curr. Opin. Neurobiol. 1999, 9:209-213.
11. Finberg J.P., Tenne M. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br. J. Pharmacol. 1982, 77:13-21.
12. Finberg J.P., Youdim M.B.H. Potentiation of tyramine pressor responses in conscious rats by reversible inhibitors of monoamine oxidase. J.Neural Transm. Suppl. 1988, 26:11-16.
13. Gal S., Abassi Z.A., Youdim M.B. Limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30. Neurotox. Res. 2010, 18:143-150.
14. Gal S., Zheng H., Fridkin M., Youdim M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. Invivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J.Neurochem. 2005, 95:79-88.
15. Gal S., Zheng H., Fridkin M., Youdim M.B. Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox. Res. 2010, 17:15-27.
16. Gassen M., Glinka Y., Pinchasi B., Youdim M.B. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 1996, 308:219-225.
17. Gerlach M., Double K.L., Youdim M.B., Riederer P. Potential sources of increased iron in the substantia nigra of Parkinsonian patients. J.Neural Transm. Suppl. 2006, 70:133-142.
18. Gerlach M., Double K.L., Youdim M.B.H., Riederer P. Strategies for the protection of dopaminergic neurons against neurotoxicty. Neurotoxicol. Res. Suppl. 2000, 2:99-114.
19. Gotz M.E., Double K., Gerlach M., Youdim M.B., Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci. 2004, 1012:193-208.
20. Greengard P., Valtorta F., Czernik A.J., Benfenati F. Synaptic vesicle phosphoproteins and regulation of synaptic function. Science 1993, 259:780-785.
21. He Y., Thong P.S., Lee T., Leong S.K., Shi C.Y., Wong P.T., Yuan S.Y., Watt F. Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: a nuclear microscopy study. Brain Res. 1996, 735:149-153.
22. Hopkins A.L., Mason J.S., Overington J.P. Can we rationally design promiscuous drugs?. Curr. Opin. Struct. Biol. 2006, 16:127-136.
23. Impey S., McCorkle S.R., Cha-Molstad H., Dwyer J.M., Yochum G.S., Boss J.M., McWeeney S., Dunn J.J., Mandel G., Goodman R.H. Defining the CREB regulon: a genome-wide analysis of transcription factor regulatory regions. Cell 2004, 119:1041-1054.
24. Jellinger K.A. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 1999, 14:115-140.
25. Jellinger K.A., Kienzl E., Rumpelmaier G., Paulus W., Riederer P., Stachelberger H., Youdim M.B.H., Ben-Shachar D. Iron and ferritin in substantia nigra in Parkinson's disease. Adv. Neurol. 1993, 60:267-272.
26. Keith C.T., Borisy A.A., Stockwell B.R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 2005, 4:71-78.
27. Kumar M.J., Andersen J.K. Perspectives on MAO-B in aging and neurological disease: where do we go from here?. Mol. Neurobiol. 2004, 30:77-89.
28. Kupershmidt L., Amit T., Bar-Am O., Youdim M.B., Weinreb O. Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice. Mech. Ageing Dev. 2012, 133:267-274.
29. Kupershmidt L., Amit T., Bar-Am O., Youdim M.B., Weinreb O. The novel multi-target iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimer's disease. Antioxid. Redox Signal 2012, 17:860-877.
30. Kupershmidt L., Weinreb O., Amit T., Mandel S., Bar-Am O., Youdim M.B. Novel molecular targets of the multi-functional brain-permeable iron chelating drug M30 in mouse brain. Neuroscience 2011, 189:345-358.
31. Kupershmidt L., Weinreb O., Amit T., Mandel S., Carri M.T., Youdim M.B. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2010, 23:3766-3779.
32. LaVaute T., Smith S., Cooperman S., Iwai K., Land W., Meyron-Holtz E., Drake S.K., Miller G., Abu-Asab M., Tsokos M., Switzer R., Grinberg A., Love P., Tresser N., Rouault T.A. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 2001, 27:209-214.
33. Li Q., Zhao H.F., Zhang Z.F., Liu Z.G., Pei X.R., Wang J.B., Cai M.Y., Li Y. Long-term administration of green tea catechins prevents age-related spatial learning and memory decline in C57BL/6 J mice by regulating hippocampal cyclic amp-response element binding protein signaling cascade. Neuroscience 2009, 159:1208-1215.
34. McKinney B.C., Oh H., Sibille E. Age-by-disease biological interactions: implications for late-life depression. Front. Genet. 2012, 3:237.
35. Meck J.V., Martin D.S., D'Aunno D.S., Waters W.W. Pressor response to intravenous tyramine is a marker of cardiac, but not vascular, adrenergic function. Cardiovasc. Pharmacol. 2003, 41:126-131.
36. Mendez J.S., Finn B.W. Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats. J.Neurosurg. 1975, 42:166-173.
37. Pirondi S., Kuteeva E., Giardino L., Ferraro L., Antonelli T., Bartfai T., Ogren S.O., Hokfelt T., Calza L. Behavioral and neurochemical studies on brain aging in galanin overexpressing mice. Neuropeptides 2005, 39:305-312.
38. Poo M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2001, 2:24-32.
39. Schindowski K., Belarbi K., Buee L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav. 2008, 7(Suppl. 1):43-56.
40. Shemyakov S.E. Monoamine oxidase activity, lipid peroxidation, and morphological changes in human hypothalamus during aging. Bull. Exp. Biol. Med. 2001, 131:586-588.
41. Simola N., Bustamante D., Pinna A., Pontis S., Morales P., Morelli M., Herrera-Marschitz M. Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats. Exp. Brain Res. 2008, 185:595-601.
42. Tipton K.F., McCrodden J.M., Kalir A.S., Youdim M.B. Inhibition of rat liver monoamine oxidase by alpha-methyl- and N-propargyl-amine derivatives. Biochem. Pharmacol. 1982, 31:1251-1255.
43. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970, 24:485-493.
44. Wang Q., Zhang X., Chen S., Zhang X., Zhang S., Youdium M., Le W. Prevention of motor neuron degeneration by novel iron chelators in SOD1G93A transgenic mice of amyotrophic lateral sclerosis. Neurodegener. Dis. 2011, 8:310-321.
45. Weinreb O., Amit T., Bar-Am O., Youdim M.B. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog. Neurobiol. 2010, 92:330-344.
46. Weinreb O., Amit T., Bar-Am O., Youdim M.B. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr. Drug Targets 2012, 13:483-494.
47. Wree A., Mix E., Hawlitschka A., Antipova V., Witt M., Schmitt O., Benecke R. Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease. Neurobiol. Dis. 2011, 41:291-298.
48. Youdim M.B., Buccafusco J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 2005, 26:27-35.
49. Youdim M.B., Kupershmidt L., Amit T., Weinreb O. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease. Parkinsonism Relat. Disord. 2014, 20(Suppl. 1):S132-S136.
50. Youdim M.B., Stephenson G., Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. N. Y. Acad. Sci. 2004, 1012:306-325.
51. Zecca L., Youdim M.B.H., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004, 5:863-873.
52. Zheng H., Gal S., Weiner L.M., Bar-Am O., Warshawsky A., Fridkin M., Youdim M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: invitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J.Neurochem. 2005, 95:68-78.
53. Zheng H., Weiner L.M., Bar-Am O., Epsztejn S., Cabantchik Z.I., Warshawsky A., Youdim M.B., Fridkin M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg. Med. Chem. 2005, 13:773-783.
54. Zhu W., Xie W., Pan T., Xu P., Fridkin M., Zheng H., Jankovic J., Youdim M.B., Le W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. Faseb J. 2007, 21:3835-3844.
55. Zigmond M.J., Stricker E.M. Parkinson's disease: studies with an animal model. Life Sci. 1984, 35:5-18.